European Heart Journal Advance Access originally published online on March 10, 2005
European Heart Journal 2005 26(9):906-913; doi:10.1093/eurheartj/ehi184
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure
1Department of Cardiology, The Cardiovascular Institute, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden
2Department of Clinical Physiology, The Cardiovascular Institute, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden
3Clinical Neurocardiology Section, NINDS, National Institutes of Health, Bethesda, MD, USA
4Baker Heart Research Institute, Melbourne, Australia
Received 19 August 2004; revised 20 January 2005; accepted 27 January 2005; online publish-ahead-of-print 10 March 2005.
* Corresponding author. Tel: +46 31 3424222; fax: +46 31 827614. E-mail address: magnus.petersson{at}wlab.gu.se
See page 861 for the editorial comment on this article (doi:10.1093/eurheartj/ehi220)
Aims Although cardiac sympathetic activation is associated with adverse outcome in patients with chronic heart failure (CHF), the influence of renal sympathetic activity on outcome is unknown. We assessed the hypothesis that renal noradrenaline (NA) spillover is a predictor of the combined endpoint of all-cause mortality and heart transplantation in CHF.
Methods and results Sixty-one patients with CHF, New York Heart Association (NYHA) I–IV (66% NYHA III–IV), and left ventricular ejection fraction (LVEF) 26±9% (mean±SD) were studied with cardiac and renal catheterizations at baseline and followed for 5.5±3.7 years (median 5.5 years, range 12 days to 11.6 years). Nineteen deaths and 13 cases of heart transplantation were registered. Only renal NA spillover above median, 1.19 (interquartile range 0.77–1.43) nmol/min, was independently associated with an increased relative risk (RR) of the combined endpoint (RR 3.1, 95% CI 1.2–7.6, P=0.01) in a model also including total body NA spillover, LVEF, glomerular filtration rate (GFR), renal blood flow, cardiac index, aetiology, and age.
Conclusion Renal noradrenergic activation has a strong negative predictive value on outcome independent of overall sympathetic activity, GFR, and LVEF. These findings suggest that treatment regimens that further reduce renal noradrenergic stimulation could be advantageous by improving survival in patients with CHF.
Key Words: Heart failure • Congestive • Survival analysis • Sympathetic nervous system • Noradrenaline • Renal circulation
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- More hormones spilt in heart failure: linking renal sympathetic activation to clinical outcome
- Jens Peter Goetze and Regitze Videbaek
EHJ 2005 26: 861-862.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  M. P. Schlaich, P. A. Sobotka, H. Krum, R. Whitbourn, A. Walton, and M. D. Esler Renal Denervation as a Therapeutic Approach for Hypertension: Novel Implications for an Old Concept Hypertension, December 1, 2009; 54(6): 1195 - 1201. [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Goetze and R. Videbaek More hormones spilt in heart failure: linking renal sympathetic activation to clinical outcome Eur. Heart J., May 1, 2005; 26(9): 861 - 862. [Full Text] [PDF]
|
|